Skip to main content

Clinical Trials Search at Vanderbilt-Ingram Cancer Center



Study of Oral LY3410738 in Patients With Advanced Hematologic Malignancies With IDH1 or IDH2 Mutations

Multiple Cancer Types

This is an open-label, multi-center Phase 1 study of LY3410738, an oral, covalent IDH inhibitor, in patients with IDH1 and / or IDH2-mutant advanced hematologic malignancies who have received standard therapy
Hematologic, Leukemia, Myelodysplastic Syndrome, Phase I
I
Byrne, Michael
NCT04603001
VICCHEMP2061

To learn more about any of our clinical
trials, call 1-800-811-8480 or complete
the online Self-Referral Form here: